Renal Cell Carcinoma (RCC) — Deal Benchmarks & Valuation
Market Analysis
Renal Cell Carcinoma (RCC) is one of the most actively transacted indications in oncology licensing. Phase 2 deals for renal cell carcinoma (rcc) carry a median total deal value of $1.4B, with upfront payments ranging from $126M to $320M. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for renal cell carcinoma (rcc) licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating